CG Oncology (CGON) Competitors

Roivant Sciences (NASDAQ:ROIV) and CG Oncology (NASDAQ:CGON) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Which has more volatility & risk, ROIV or CGON?

Roivant Sciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, CG Oncology has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Which has stronger valuation and earnings, ROIV or CGON?

CG Oncology has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than CG Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$29.05M	266.54	-$171.98M	-$0.25	-45.56
CG Oncology	$662K	3,030.58	-$88.04M	-$1.51	-17.43

Is ROIV or CGON more profitable?

Roivant Sciences has a net margin of -225.71% compared to CG Oncology's net margin of -15,945.17%. Roivant Sciences' return on equity of -14.76% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-225.71%	-14.76%	-13.69%
CG Oncology	-15,945.17%	-16.71%	-16.24%

Does the media prefer ROIV or CGON?

In the previous week, CG Oncology had 7 more articles in the media than Roivant Sciences. MarketBeat recorded 8 mentions for CG Oncology and 1 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.63 beat CG Oncology's score of 0.21 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CG Oncology	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals hold more shares of ROIV or CGON?

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate ROIV or CGON?

Roivant Sciences currently has a consensus price target of $16.50, indicating a potential upside of 44.86%. CG Oncology has a consensus price target of $55.30, indicating a potential upside of 110.11%. Given CG Oncology's higher probable upside, analysts plainly believe CG Oncology is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.25
CG Oncology	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.08

Summary

Roivant Sciences beats CG Oncology on 10 of the 16 factors compared between the two stocks.